At ESMO 2024, new studies show that immunotherapy can benefit women with early-stage endometrial and cervical cancers. One study found promising results with an antibody drug conjugate targeting a specific protein in ovarian and endometrial cancers. Immunotherapy has improved survival in many cancers, but its efficacy in gynecological cancers varies. Pembrolizumab with chemoradiotherapy improved overall survival in high-risk cervical cancer. Subgroup analysis in endometrial cancer revealed benefits for patients with deficient mismatch repair tumors. Future research will focus on identifying subgroups that benefit from immunotherapy. New treatment options and personalized therapies are being explored to improve outcomes in gynecological cancers.
Source link
Antibody-drug conjugate shows promise in treating ovarian and endometrial cancers
